Elan Corp Plc
—- Market cap
- —
- Debt
- +$904.20M
- Cash
- −$599.20M
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: Elan Corp Plc stock price vs CTXR: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CTXR's multiple
Needs EPS (TTM), CTXR P/E.
Implied fair value · at Elan Corp Plc's multiple
Needs EPS (TTM) is negative, Elan Corp Plc P/E.
Engine logicElan Corp Plcvalued onCTXR’smultiple
Metric by metric
Snapshot Sep 4, 4:00 PM ET
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: Elan Corp Plc FY 2012 (ended Dec 31, 2012) · CTXR FY 2022 (ended Sep 30, 2022). Fiscal years are not aligned.
Trendline
13 fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 161% equity / -61% debt · EV / EBITDA 0.96x
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ELAN CORP PLC · implied price per share
The ordinary-share to listed-security ratio could not be verified.
Citius Pharmaceuticals, Inc. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
1.46x
-0.06x
Net debt / EBITDA
Leverage against operating earnings
-0.64x
1.45x
Cash and equivalents
Liquid reserves on the balance sheet
$599.20M
$41.71M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
$904.20M
-$6.11M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.